Truist raised the price target for the Antares Pharma Inc. (NASDAQ:ATRS) stock to “a Buy”. The rating was released on July 16, 2021. We previously noted in another research note published on October 23, 2017 by H.C. Wainwright that reiterated the stock to a Buy with a price target of $3.50 for ATRS stock. The research report from H.C. Wainwright has initiated the stock to Buy, with a price target set at $5. In their research brief published May 28, 2015, Jefferies analysts initiated the Antares Pharma Inc. stock to Buy with a price target of $5.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Antares Pharma Inc. (NASDAQ:ATRS) dipped -3.07% to close Friday’s market session at $4.10, lower as compared to yesterday’s close. The stock price fluctuated between $4.07 and $4.26 throughout the trading session with the volume trading being 854066 shares, which represented a significant variation when compared to the three months average volume of 842.14K shares. The firm’s stock price fluctuated -6.82% within the last five trades and -4.87% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -12.39% in the last 6 months and 7.05% was added to its value over the previous 3 months. ATRS stock is trading at a margin of -5.76%, -4.75% and 3.05% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, ATRS deals in the Healthcare domain. The stock is trading -19.13 percent below its 52-week high and 59.53 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 31.86. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Antares Pharma Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 12.80 percent and the profit margin is 39.30 percent, and the company has reported a gross margin of 59.30 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $699.99 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Antares Pharma Inc. (NASDAQ:ATRS) is 11.26. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 15.59. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 4.41 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 5.47, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 3.00 percent of Antares Pharma Inc. shares are owned by insiders, and 49.50 percent are held by financial institutions. GUETH ANTON, the Director at Antares Pharma Inc. (ATRS) has sold 100,000 shares of firm on Jul 08 at a price of $4.29 against the total amount of $0.43 million. In another inside trade, GARRITY THOMAS J, Director of Antares Pharma Inc. (NASDAQ:ATRS) sold 50,000 shares of the firm on Mar 11 for a total worth of $0.21 million at a price of $4.28. An inside trade which took place on Feb 18, EVP General Counsel, Secretary of Antares Pharma Inc. GRAHAM PETER J sold 45,000 shares of firm against total price of $0.22 million at the cost of $4.93 per share.